Canada · Delayed Price · Currency is CAD MedMira Company Description
MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, and internationally.
The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV and hepatitis.
It also provides the Miriad RVF toolkit, which facilitates the development and commercialization of rapid diagnostics; and REVEALCOVID-19 and Reveal G4 HIV tests.
The company distributes its products through a network of medical distributors and strategic business development partners, serving customers in various healthcare sectors, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies.
The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.
Contact Details
Address: 155 Chain Lake Drive Halifax, Alberta B3S 1B3 Canada | |
| Phone | 902 450 1588 |
| Website | medmira.com |
Stock Details
| Ticker Symbol | MIR |
| Exchange | TSX Venture Exchange |
| Fiscal Year | August - July |
| Reporting Currency | CAD |
| ISIN Number | CA58501R1029 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Hermes Chan | Co-Founder, Chief Executive Officer, President and Director |
| Markus M. Meile | Chief Financial Officer |
| Dr. Sam Ratnam | Director of Scientific and Regulatory Affairs |
| Stewart McKelvey | Legal Counsel |